**EXHIBIT 10.4**

**SEPARATIONAGREEMENT****AND****GENERAL RELEASE OF CLAIMS**

This Separation Agreement and General Release ofClaims (hereinafter “Agreement”) is entered into by and between Robert E. Sobol, M.D. (hereinafter “Employee”) and Corautus Genetics Inc. (hereinafter “Corautus” or “Company”).

**RECITALS**

A.

Corautus (formerly known as GenStar Therapeutics Corporation) is a corporation and is doing business in the State of California.

B.

Employee has been employed by Corautus as President.

C.

Effective March 31, 2003, Employee willresign his position with Corautus to pursue other interests. 

D.

Employee desires to settle and compromise any and all possible claims and disputes he has against Corautus arising out of their relationship todate, and to provide for a General Release of any and all such claims. 

**AGREEMENT**

1.

Termination of Employment.

a.

Employee agrees that his resignation from employment withCorautus shall be effective and that his employment relationship with Corautus shall terminate as of March 31, 2003. 

b.

Corautus shall pay Employee the sum of Ninety-Three Thousand Five Hundred Ninety-Three and 46/100 Dollars ($93,593.46) less applicable payroll taxes, on the eighth day after execution hereof in complete and full satisfaction of all accrued wages, salary and vacation pay owed by Corautus to Employee. 

c.

Employee hereby resigns as President and Director ofCorautus effective March 31, 2003. 

2.

Separation Pay/Consideration.

Eight (8) days after Employee’s execution of this Agreement, Employee shall become eligible to receive thefollowing consideration:

a.

In consideration ofthe covenants and releases of all claims other than Age Discrimination in Employment Act of 1967 (“ADEA”) claims given herein, Corautus will provide the following consideration to Employee: 

i.

Corautus will issue to Employee options for 50,000shares of Common Stock of Corautus at an exercise price of $.01 per share. Shares of Common Stock issued pursuant to the exercise of such options will be subject to the GenStar Stockholders Agreement among GenStar Therapeutics Corporation, Employeeand others dated September 12, 2002. 

ii.

Corautus will extend the time period to exercise vested Corautus stock options from 90 days from the termination of employment date as set forth in Section 1 of this Agreement, to two (2) years from the termination of employment date as setforth in Section 1 of this Agreement. 

iii.

Corautus will continue to provide the existing medical and life insurance coverage elected by Employee under Corautus’s group health insurance and life insurance plans or will provide comparable medical insurance coverage to Employee andhis spouse and eligible dependent children for a period of six (6) months from March 31, 2003, with Corautus to pay the entire premium for such coverage. 

iv.

As additional consideration for the favorable provisions in this Agreement, Corautus agrees to assign to Employee oran entity designated by him, to the extent assignable, all of its right, title and interest, if any, which Corautus now has, in and to the grants, pending grants, patents and patent applications listed on Exhibit A and the intellectual property orinventions of Corautus which are solely associated therewith, together with all reasonably related written, graphic and/or machine readable materials, research and development documentation, grant related documents and reagents reasonably associatedtherewith (collectively “Property”); provided that (A) all such assignments of the Property will be AS IS and without any representation or warranty of any kind, express or implied, and subject to all liabilities, defects or encumbrancesassociated therewith; (B) Corautus is released in writing by all applicable parties from all obligations and liabilities, whenever arising, with respect to such grants, pending grants, patents, patent applications and licenses and as part of and asa condition to such transfers, and such parties agree to look solely to Employee or the entity designated by him for all performance required in connection therewith; (C) Employee will have the burden and sole expense of obtaining all neededconsents and preparing all agreements and documents for all such transfers, which shall comply with the foregoing and shall be subject to Corautus’s review and approval.

2

v.

Corautus agrees toexecute such reasonably required additional documents and perform such reasonable acts as are reasonably necessary to effectuate the intent of this Agreement, including without limitation the assignment set forth in subsection iv above, which arenot, in Corautus’ sole opinion, unduly burdensome. Further, effective immediately upon such assignment, Corautus shall have no right or obligation to: (1) continue prosecution of patent applications that are part of the Property; (2) maintainany existing patents that are part of the Property; (2) enforce any patents; or (3) take any action in furtherance of prosecuting or exploiting patent applications, patents, grants or pending grants. 

b.

In consideration of the covenants and releases of allADEA claims given herein, Corautus will issue to Employee options for 50,000 shares of common stock of Corautus at an exercise price of $.01 per share, such shares being in addition to the shares under 2(a)(i) above. Shares of Common Stock issuedpursuant to the exercise of such options will be subject to the GenStar Stockholders Agreement among GenStar Therapeutics Corporation, Employee and others dated September 12, 2002

c.

Release of All Claims Except ADEAClaims.

a.

In consideration of the separationpayment/consideration described in Section 2a of this Agreement, which Employee would otherwise not be entitled to except for signing this Agreement, Employee does hereby unconditionally, irrevocably and absolutely release and discharge Corautus,its owners, directors, officers, employees, agents, attorneys, stockholders, insurers, divisions, predecessors, successors and assigns, and any related holding, parent, sister or subsidiary corporations from any and all loss, liability, claims,demands, causes of action or suits of any type, whether in law and/or in equity, related directly or indirectly, or in any way connected with any transaction, affairs or occurrences between them to date, including, but not limited to,Employee’s employment with Corautus and the termination of said employment. This Agreement specifically applies, without limitation, to any and all contract or tort claims, claims for wrongful termination, and claims arising under Title VII ofthe Civil Rights Act of 1991, the Americans with Disabilities Act, the Equal Pay Act, the California Fair Employment and Housing Act, the Fair Labor Standards Act, the Family and Medical Leave Act, the California Family Rights Act, the CaliforniaLabor Code, the Employee Retirement Income Security Act of 1974, and any and all federal or state statutes or provisions governing discrimination in employment except the federal statute specifically excluded hereafter. This release specificallyexcludes any and all loss, liability, claims, demands, causes of action or suits of any type arising under the ADEA. Employee’s release of ADEA claims will be addressed separately in Section 2(d) of this Agreement.

3

b.

Employee does expressly waive all of the benefitsand rights granted to him pursuant to California Civil Code section 1542, which reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TOCLAIMS WHICH THE CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

Employee does certify that he has read all of this Agreement, including the release provisions contained herein and the quoted Civil Code section, and that he fully understands all of the same.Employee hereby expressly agrees that this Agreement shall extend and apply to all unknown, unsuspected and unanticipated injuries and damages, as well as those that are now disclosed.

c.

Employee irrevocably and absolutely agrees that he will not prosecute nor allow to beprosecuted on his behalf, in any administrative agency, whether federal or state, or in any court, whether federal or state, any claim or demand of any type related to the matters released above, it being the intention of the parties that with theexecution by Employee of this release, Corautus, its owners, directors, officers, employees, agents, attorneys, stockholders, insurers, divisions, predecessors, successors and assigns, and any related holding, parent, sister or subsidiarycorporations will be absolutely, unconditionally and forever discharged of and from all obligations to or on behalf of Employee related in any way to the matters discharged herein.

d.

Release of All ADEA Claims.

a.

This section of the Agreement exclusively addressesEmployee’s release of claims arising under federal law involving discrimination on the basis of age in employment (age forty and above). This section is provided separately, in compliance with federal law, including but not limited to the OlderWorkers’ Benefit Protection Act of 1990, to ensure that Employee clearly understands his rights so that any release of age discrimination claims under federal law (the Age Discrimination in Employment Act of 1967 (“ADEA”)) is knowingand voluntary on the part of Employee.

b.

Employee represents,acknowledges and agrees that Corautus has advised him, in writing, to discuss this Agreement with an attorney, and to that extent, if any, that Employee has desired, Employee has done so; that Corautus has given Employee forty-five (45) days fromreceipt of this Agreement to review and consider this Agreement before signing it, and Employee

4

understands that he may use as much of this forty-five (45) day period as he wishes prior to signing; and that no promise,representation, warranty or agreements not contained herein have been made by or with anyone to cause him to sign this Agreement; that he has read this Agreement in its entirety, and fully understands and is aware of its meaning, intent, content andlegal effect; and that he is executing this release voluntarily and free of any duress or coercion.

c.

Employee represents, acknowledges and agrees that he has reviewed Exhibit B, attached to this Agreement, which sets forth thejob titles and ages of employees whose current position have been impacted by the reorganization and the relevant job titles and ages of employees who were not impacted by the reorganization.

d.

The parties acknowledge that for a period of seven (7) days following theexecution of this Agreement, Employee may revoke the Agreement, and the Agreement shall not become effective or enforceable until the revocation period has expired. This Agreement shall become effective eight (8) days after it has been signedby Employee and Corautus, and in the event the parties do not sign on the same date, then this Agreement shall become effective eight (8) days after the date it is signed by Employee. 

e.

In consideration of the separation payment made to Employee described in Section 2bof this Agreement, which Employee would otherwise not be entitled to except for signing this Agreement, Employee does hereby unconditionally, irrevocably and absolutely release and discharge Corautus, its owners, directors, officers, employees,agents, attorneys, stockholders, insurers, divisions, predecessors, successors and assigns, and any related holding, parent, sister or subsidiary corporations from any and all loss, liability, claims, demands, causes of action or suits of any typearising under the ADEA and related directly or indirectly to Employee’s employment with Corautus and the termination of said employment. 

f.

Employee does expressly waive all of the benefits and rights granted to him pursuant to California Civil Code section 1542, which reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IFKNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

5

Employee does certify that he has read all of this Agreement, including the release provisions contained herein and the quoted Civil Codesection, and that he fully understands all of the same. Employee hereby expressly agrees that this Agreement shall extend and apply to all unknown, unsuspected and unanticipated ADEA injuries and damages, as well as those ADEA injuries and damagesthat are now disclosed.

e.

Confidentiality/Non-Disparagement.

Employee agrees that all matters relative to this Agreement shall remain confidential.Accordingly, Employee hereby agrees that, with the exception of his spouse, counsel and tax advisors, he shall not discuss, disclose or reveal to any other persons, entities or organizations, whether within or outside of Corautus, the terms andconditions of this Agreement. Employee agrees not to make any derogatory or adverse statements, written or verbal, regarding Corautus or any of its present or former directors, officers or employees, to anyone. Additionally, Employee acknowledgesand reaffirms responsibility under the Confidential Information and Inventions Assignment Agreement signed upon employment with Corautus.

f.

Entire Agreement. 

TheParties further declare and represent that no promise, inducement or agreement not herein expressed has been made to them and that this Agreement contains the full and entire agreement between and among the Parties, and that the terms of thisAgreement are contractual and not a mere recital.

g.

Applicable Law. 

Thevalidity, interpretation, and performance of this Agreement shall be construed and interpreted according to the laws of the State of California.

h.

Dispute Resolution. 

Anydispute arising out of or related to this Agreement shall be resolved through binding arbitration through JAMS/Endispute in San Diego, California, under the then current applicable rules of JAMS/Endispute. Each party shall be responsible for its orhis own costs and attorneys’ fees in connection with the arbitration.

i.

Complete Defense.

ThisAgreement may be pleaded as a full and complete defense against any action, suit or proceeding which may be prosecuted, instituted or attempted by either party in breach thereof.

j.

Severability.

6

If any provision of this Agreement, or part thereof, is held invalid, void or voidable as against public policy or otherwise, theinvalidity shall not affect other provisions, or parts thereof, which may be given effect without the invalid provision or part. To this extent, the provisions, and parts thereof, of this Agreement are declared to be severable. 

k.

No Admission of Liability.

It is understood that this Agreement is not an admission of any liability by any person, firm, association or corporation but is in compromise of adisputed claim.

l.

Successors andAssigns.

This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legalrepresentatives, successors and assigns.

**IN WITNESS WHEREOF**, the undersigned have executed this Agreement on the dates shownbelow.

  

 

 

 

Dated: April 4, 2003

 

/s/ ROBERT E. SOBOL, M.D.

 

 

 

 

**Robert E. Sobol, M.D.**

 

 

 

Corautus Genetics Inc.

Dated: April 4, 2003

 

By: 

/s/ RICHARD E. OTTO

 

 

 

 

 

**Richard E. Otto, Chief Executive Officer**

7

**EXHIBIT A**

**Grants**

 

 

 

 

**Number/Status/Duration**

 

**Title/Purpose**

R43 A1054065-01

 

PEGylation of Max-Ad Vectors to Enhance Gene Delivery

R43 AI055121-01

 

Liposome Enhancement of Max-Ad Vector Gene Delivery

R43 AI50324-02

 

A Max-Ad Vaccine for Mucosal Immunity to HIV

R43 CA 83156

 

Complimentary Adenoviral Vectors for Treatment of Prostate Cancer (Phase I)

R44 CA 83156

 

Complimentary Adenoviral Vectors for Treatment of Prostate Cancer (Phase II)

R44 HL 63477-03

 

A Max-Ad Vector for Treatment of Hemophilia Factor VIII Deficiency

**Licenses to Cover the Following Patents and Patent Applications**

 

 

**INDEX TO FOREIGN PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Patent Issued**

 

**Location**

**MINI-AD**

1

 

96,2087-B(PCT)

 

Mini Ad VectorFiled: 12/4/97

 

Zhang et al

 

PCT/US97/10218

 

 

 

 

 

RES 3-1

1.1

 

96,2087-B(PCT)

 

References to #1

 

Zhang et al

 

PCT/US97/10218

 

 

 

 

 

RES 3-1

1.2

 

96,2087-B(PCT)

 

References to #1

 

Zhang et al

 

PCT/US97/10218

 

 

 

 

 

RES 3-1

1.3

 

96,2087-B(PCT)

 

References to #1

 

Zhang et al

 

PCT/US97/10218

 

 

 

 

 

RES 3-1

2

 

96,2087-D(PCT)

 

Factor VIII Mini-Ad VectorFiled: 12/18/97CASE WITHDRAWN PER 

 

Josephs, et al

 

 

 

 

 

 

 

RES 3-1

8

 

**INDEX TO FOREIGN PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Patent Issued**

 

**Location**

 

 

 

 

EMILY MAIO 1/14/98

 

 

 

 

 

 

 

 

 

 

3

 

96,2087-E(PCT)

 

Factor VIII Mini-Ad VectorFiled: 05/19/98

 

Zhang et al

 

PCT/US98/10330

 

 

 

 

 

RES 3-1

4

 

96,2087-F(EPO)

 

 

 

 

 

 

 

 

 

 

 

 

5

 

96,2087-G(CAN)

 

 

 

 

 

 

 

 

 

 

 

 

6

 

96,2087-H(JP)

 

 

 

 

 

 

 

 

 

 

 

 

7

 

96,424-I(PCT)

 

Mini-Adenoviral Vector System for VaccinationFiled: 7/20/01

 

 

 

 

 

 

 

 

 

 

8

 

96,2087-O

 

Mini-Ad Vector for ImmunizationFiled: 4/18/02

 

 

 

PCT/US02/12237

 

 

 

 

 

 

**CELL LINES**

9

 

96,424-C(PCT)

 

Adenovirus E-1Complimenting Cell LinesFiled: 2/23/98

 

Ayares, et al

 

PCT/US98/03473

 

 

 

 

 

RES 3-1

10

 

96,424-D(EPO)

 

Adenovirus E-1Complimenting Cell Lines

 

Ayares, et al.

 

98 908 661.6

 

 

 

 

 

RES 3-1

11

 

96,424-E(CAN)

 

 

 

 

 

 

 

 

 

 

 

 

12

 

96,424-F(JP)

 

 

 

 

 

 

 

 

 

 

 

 

**DUAL-AD SYSTEM**

13

 

97,087-A(PCT)

 ****

**AN ONCOLYTIC/IMMUNOGENICCOMPLEMENTARY-ADENOVIRAL VECTOR SYSTEM**

 

Alemany et al.

 

PCT/US98/01301

 

 

 

WO 98/3502808/13/98

 

RES 3-1

14

 

97,087-C(EPO)

 

 

 

 

 

 

 

 

 

 

 

 

15

 

96,424-D(JP)

 

 

 

 

 

 

 

 

 

 

 

 

16

 

96,424-E(CAN)

 

 

 

 

 

 

 

 

 

 

 

 

**BASIC AD VECTORS**

17

 

96,2088-A(PCT)

 

Methods for Highly Efficient Generation of Adenoviral VectorsFiled: 12/19/97

 

Dai

 

PCT/US/97/23685

 

 

 

WO98/3286007/30/98

 

RES 3-1

9

 

**INDEX TO FOREIGN PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Patent Issued**

 

**Location**

17.1

 

96,2088-A(PCT)

 

References for #16

 

Dai

 

PCT/US/97/23685

 

 

 

WO98/3286007/30/98

 

RES 3-1

 

 

**INDEX TO RADIATION SENSITIZATION PATENTS****[CAMPBELL & FLORES]**

 

 

**UCLA****Ref.**

 

**C&F****Docket**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Patent**

 

**Issued**

 

**Location**

1.

 

LA 96-569-1

 

P-UL-1932

 

Tumor Radiosensitization using Gene Therapy; Filed: 2/2/96

 

McBride

 

US 08/597,524

 

US 6,051,218

 

4/18/00

 

RES 3-3

2.

 

LA 96-569-01

 

P-UL-1932

 

Tumor Radiosensitization using Gene Therapy [CIP 08/597,524; filed 1/23/98

 

McBride

 

08/597,524

 

LA 96-569-01

 

 

 

RES 3-3

3.

 

LA 96-569-2

 

P-UL 4032

 

Tumor Radiosensitization using Gene Therapy; filed 3/24/00

 

McBride

 

09/535,654

 

LA 96-569-2

 

 

 

RES 3-3

4.

 

LA 96-569-1

 

FP-UL 2407

 

Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]

 

McBride

 

PCT/US97/01465

 

 

 

 

 

RES 3-3

5.

 

LA 96-569-1

 

FP-UL 3204

 

Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]

 

McBride

 

Canada Pat. App: 2,244,841

 

 

 

 

 

RES 3-3

6.

 

LA 96-569-01

 

FP-UL 3205

 

Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]

 

McBride

 

Europe Pat. App: 97904085.4

 

 

 

 

 

RES 3-3

7.

 

LA 96-569-1

 

FP-UL 3206

 

Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]

 

McBride

 

Japanese Pat. App: 9-527808

 

 

 

 

 

RES 3-3

8.

 

LA 96-569-1

 

FP-UL 3896

 

Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]

 

McBride

 

Hong Kong Pat. App. 99104559.7 (European Pat. No. 0 907 720)

 

 

 

 

 

RES 3-3

 

 

**INDEX TO ADENOVIRAL VECTOR****U.S. PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Dates**

 

**Patent Issued**

 

**Location**

**MINI-AD**

1.1

 

96,424

 

Mini-Adenoviral Vector System (parent) Filed 5/31/96

 

Zhang, et al.

 

08/658,961

 

I

 

5/31//96through6/10/98

 

 

 

RES 3-2

1.2

 

96,424

 

Mini-Adenoviral Vector System (parent) 

 

Zhang, et al.

 

08/658,961

 

II

 

6/12/98through2/26/01

 

 

 

RES 3-2

10

 

**INDEX TO ADENOVIRAL VECTOR****U.S. PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Dates**

 

**Patent Issued**

 

**Location**

1.3

 

96,424

 

Mini-Adenoviral Vector System (parent)

 

Zhang, et al.

 

08/658,961

 

III

 

8/25/00 to

 

 

 

RES 3-2

2

 

96,424-G

 

Mini-Adenoviral Vector System for Vaccination (Continuation of 96,424)**FILED:7/20/00**

 

Zhang, et al

 

08/619,938

 

 

 

 

 

 

 

RES 3-2

3

 

96,2087

 

Factor VIII Mini-Ad Vector (CIP of 96,424)Filed 1/27/97**ABANDONED**

 

Josephs et al

 

08/791,021

 

 

 

 

 

 

 

RES 3-2

4.1

 

96,2087-A

 

Factor VIII Mini-Ad Vector (CIP of 96,424)Filed 1/13/97

 

Josephs, et al

 

08/791,218

 

I

 

1/31/97 through 4/99

 

 

 

RES 3-2

4.2

 

96,2087-A

 

Factor VIII Mini-Ad Vector (CIP of 96,424)Filed 1/13/97

 

Josephs, et al

 

08/791,218

 

II

 

4/99 to 2/16/01

 

 

 

RES 3-2

5.1

 

96,2087-C

 

Mini-Ad Vector (CIP of 96,424 and 96,2087-A)Filed: 5/30/97; Amended 10/23/97

 

Zhang, et al.

 

08/866,403

 

I

 

8/21/97 to 1/19/99

 

 

 

RES 3-2

5.2

 

96,2087-C

 

Mini-Ad Vector (CIP of 96,424 and 96,2087-A)Filed: 5/30/97; Amended 10/23/97

 

Zhang, et al.

 

08/866,403

 

II

 

8/19/99 to 12/26/00

 

 

 

RES 3-2

6

 

96,2087-I

 

Minimal Adenoviral Vector System for FVIII Gene Therapy (Cont of 96,2087-C)Filed: 4/18/01

 

Zhang et al

 

09/837,079

 

 

 

 

 

 

 

RES 3-2

7

 

96,2087-J

 

Development and Application of a Minimal- Adenoviral Vector System for Gene Therapy of Hemophilia A: Thrombosis and Haemostasis, 82(2): 562-571 (1999)[Provisional APPLICATION WITH NEW DATA, incorporated into 96,2087-LFiled: 4/18/00

 

Zhang, et al

 

60,197,734

 

 

 

 

 

 

 

RES 3-2

8

 

96,2087-K

 

Sustained High-Level Expression of Full-Length Human Factor VIII and Restoration of Clotting Activity in Hemophilic Mice Using Minimal Adenovirus Vector.Blood, 95(3): 820 (2/1/00) [Provisional, incorporated into 96,2087-L] 

 

Balague, et al

 

60,198,501

 

 

 

 

 

 

 

RES 3-2

11

 

**INDEX TO ADENOVIRAL VECTOR****U.S. PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Dates**

 

**Patent Issued**

 

**Location**

 

 

 

 

Filed: 4/18/00

 

 

 

 

 

 

 

 

 

 

 

 

9

 

96,2087-L

 

Mini-Ad Vector and Methods of Using Same [Provisional Application; includes data from 96,2087 J & K, and the use of immunomodulators (i.e., anti-CD4 withmini-AD.Filed: 5/1/01 

 

Fang andHariharan

 

60/287,850

 

 

 

 

 

 

 

RES 3-2

10

 

MBHB00-1104

 

Mini-Ad Mediated Recombinant Vaccine [Provisional App]Filed 10/10/00

 

Fang

 

Prov: 60/239,224

 

 

 

 

 

 

 

RES 3-2

11

 

MBHB00-1130

 

HIV/HPV Mini-Ad Vaccine [Provisional App]Filed 10/19/00

 

Fang 

 

Prov: 60/241,625

 

 

 

 

 

 

 

RES 3-2

**CELL LINES**

12.1

 

96,424-B

 

Adenovirus E1-Complementing Cell Lines (CIP of 96,424)Filed: 3/4/97Unintentionally abandoned and revived as96,424-H

 

Ayares, et al.

 

08/810,039

 

I

 

 

 

 

 

RES 3-2

12.2

 

96,424-B

 

Adenovirus E1-Complementing Cell Lines (CIP of 96,424)Filed: 3/4/97Unintentionally abandoned and revived as96,424-H

 

Ayares, et al.

 

08/810,039

 

II

 

 

 

 

 

RES 3-2

13

 

96,424-H

 

Adenovirus E-1 Complementing Cell Lines (Continuation of 96,424-B, which was unintentionally abandoned Filed: 2/8/01 with request to revive 96,424-B, whichwas granted

 

Ayares, et al

 

09/779,570

 

 

 

 

 

 

 

RES 3-2

**DUAL-AD SYSTEM**

14.1

 

97,087

 

Oncolytic/Immunogenic Complementary Adenoviral Vector System Filed: 2/10/97 

 

Alemany, et al

 

08/797,160

 

I

 

2/10/97through5/30/00

 

 

 

RES 3-2

14.2

 

97,087

 

Oncolytic/Immunogenic Complementary Adenoviral Vector SystemFiled: 2/10/97; Cont. 5/22/02**Patent issued6/11/02**

 

Alemany, et al

 

08/797,160

 

II

 

8/11/00through2/12/01

 

US 6,403,370B1 

 

RES 3-2

12

 

**INDEX TO ADENOVIRAL VECTOR****U.S. PATENT FILES [MBHB]**

**No.**

 

**Case No.**

 

**Title**

 

**Inventor**

 

**Serial No.**

 

**Vol.**

 

**Dates**

 

**Patent Issued**

 

**Location**

15

 

97,087-B

 

Oncolytic/Immunogenic Complimentary Adenoviral Vector System [Adds new data related to liver and prostate cancer along with DNA sequences] (CIP of97,087)Filed: 3/31/00

 

Alemany, et al

 

09/539,698

 

 

 

 

 

 

 

RES 3-2

**BASIC AD VECTORS**

16.1

 

96,2088

 

Methods for Highly Efficient Generation of Adenoviral VectorsFiled: 1/28/97

 

Dai

 

08/789,886

 

I

 

1/28/97 through 5/1/98

 

 

 

RES 3-2

16.2

 

96,2088

 

Methods for Highly Efficient Generation of Adenoviral VectorsFiled: 1/28/97

 

Dai

 

08/789,886

 

II

 

6/4/98 through 2/1/01

 

 

 

RES 3-2

17

 

MBHB 01-1207

 

Methods of Treatment with Viral Vectors (TGf-Beta blocker)Filed: 9/20/01

 

 

 

60/323,644

 

 

 

 

 

 

 

 

18

 

MBHB 01-1700

 

Vaccine and Cancer Therapy Vectors (Genetic Dual Ad Contracts)Filed: 1/10/02

 

 

 

60/347,707

 

 

 

 

 

 

 

 

19

 

MBHB 02-308

 

Materials and Methods for the Production of Biological Compositions (Liposomes / PEG)Filed: 4/29/02

 

 

 

60/376,350

 

 

 

 

 

 

 

 

13